SCD-044 Tablets_Dose 1 for Atopic Dermatitis

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Site # 08, West Lafayette, INAtopic DermatitisSCD-044_Dose 1 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new medication for people with moderate to severe eczema. The study is double-blind, meaning neither the participants nor the researchers will know who is receiving the medication or the placebo.

Eligible Conditions
  • Atopic Dermatitis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

0 Primary · 11 Secondary · Reporting Duration: Week 36

Week 32
Dermatology Life Quality Index (DLQI)
Eczema Area and Severity Index (EASI) score
Patient Global Impression of Change (PGIC)
Patient Global Impression of Severity (PGIS)
Patient Oriented Eczema Measure (POEM) score
Percent body surface area (BSA)
SCORing Atopic Dermatitis (SCORAD) 50 and SCORAD 75 response
Validated Investigator's Global Assessment (vlGA) scale
Validated Investigator's Global Assessment (vlGA) scale.
Worst Itch Numeric Rating Scale (WI-NRS)
Week 36
Adverse events.

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

4 Treatment Groups

SCD-044 Tablets_Dose 1
1 of 4
SCD-044 Tablets_Dose 2
1 of 4
SCD-044 Tablets_Dose 3
1 of 4
Placebo of SCD-044 product
1 of 4

Active Control

Non-Treatment Group

240 Total Participants · 4 Treatment Groups

Primary Treatment: SCD-044 Tablets_Dose 1 · Has Placebo Group · Phase 2

Placebo of SCD-044 product
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
SCD-044 Tablets_Dose 1
Drug
ActiveComparator Group · 1 Intervention: SCD-044_Dose 1 · Intervention Types: Drug
SCD-044 Tablets_Dose 2
Drug
ActiveComparator Group · 1 Intervention: SCD-044_Dose 2 · Intervention Types: Drug
SCD-044 Tablets_Dose 3
Drug
ActiveComparator Group · 1 Intervention: SCD-044_Dose 3 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: week 36

Who is running the clinical trial?

Sun Pharmaceutical Industries LimitedLead Sponsor
59 Previous Clinical Trials
13,082 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have significant eczema at the beginning of the study.

Frequently Asked Questions

Has recruitment for this clinical experiment already begun?

"Affirmative. According to clinicaltrials.gov, this study is actively recruiting; it was first announced on July 30th 2021 and most recently modified on August 26th 2022. The research aims at enrolling 240 participants from 17 separate medical centres." - Anonymous Online Contributor

Unverified Answer

How many individuals are partaking in this investigation?

"Affirmative. According to the records found on clinicaltrials.gov, this research trial is still actively recruiting participants and has been since July 30th 2021. The study requires 240 people from 17 different sites for admission." - Anonymous Online Contributor

Unverified Answer

How many healthcare centers are conducting this research study within the state's border?

"This clinical trial is operating at 17 sites, which include Site #08 in West Lafayette, Site #12 in Encino and Site #16 in Arlington. The remaining fourteen locations are also included." - Anonymous Online Contributor

Unverified Answer

Are there any adverse effects associated with SCD-044 Tablets_Dose 1?

"Our team at Power deem SCD-044 Tablets_Dose 1 to be a moderately safe medication, assigning it a score of 2. This evaluation is based on the fact that this is currently in Phase 2, which implies there are some safety data but none for efficacy." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.